Antonella Mancuso appointed Patheon's President, Global Commercial Operations and Chief Manufacturing Officer
Previously Senior Vice President and Managing Director European Operations, Mancuso now oversees Patheon's global commercial manufacturing platform
TORONTO, Jan. 25, 2012 /PRNewswire/ - Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that Antonella Mancuso has been promoted to President, Global Commercial Operations and Chief Manufacturing Officer, responsible for Patheon's global commercial manufacturing operations . Ms. Mancuso will assume responsibility for all of Patheon's commercial operating units in North America and Europe. In her previous role as Senior Vice President and Managing Director European Operations, Ms. Mancuso managed the company's commercial manufacturing operations outside of North America.
"Antonella's demonstrated success focusing on the customer, on quality, and on margins is in direct alignment with our company strategy and directly supports the needs of our customers, our employees and our shareholders. I am excited about this opportunity to unify our manufacturing services business and leverage best practices across our business," stated Jim Mullen, Patheon's Chief Executive Officer.
Ms. Mancuso joined Patheon in 2001 as Production Manager of Patheon's facility in Monza, Italy, becoming Site Director in June 2002. She has held other positions with increasing responsibility culminating with her appointment to her new position as President, Global Commercial Operations and Chief Manufacturing Officer. Prior to joining Patheon, Ms. Mancuso held progressively senior roles in production and manufacturing during her six years at Bristol-Myers Squibb in Italy. Antonella has also worked at Select Pharma and Bioprogress. She holds a degree in Pharmaceutical Chemistry and Technology from La Sapienza University of Rome.
Patheon Inc. (TSX: PTI) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Its services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, soft gel, solid and liquid forms.
The company's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. The company's integrated development and manufacturing network of 10 manufacturing facilities, nine development centers and one clinical trial material packaging facility across North America and Europe, enables customer products to be launched with confidence anywhere in the world.
SOURCE Patheon Inc.
News Provided by Acquire Media